Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 16/20 | 0.74 |
| ▸ | EGFR | P00533 | 2/20 | 0.74 |
| ▸ | GAK | O14976 | 1/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | RAD52 | P43351 | 1/20 | 0.63 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.61 |
| ▸ | RAF1 | P04049 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4097022 | 0.85 | SRC (0.73) | SRCEGFRGAKERBB2 | |
| SCHEMBL27537981 | 0.85 | SRC (0.73) | SRCEGFRGAKERBB2 | |
| SCHEMBL3978612 | 0.85 | SRC (0.73) | SRCEGFRGAKERBB2 | |
| SCHEMBL5257082 | 0.85 | SRC (0.73) | SRCEGFRGAKMAP2K1ERBB2 | |
| SCHEMBL5251972 | 0.82 | SRC (0.80) | SRCEGFRGAKERBB2 | |
| SCHEMBL6185084 | 0.81 | SRC (0.83) | SRCEGFRGAKMAP2K1ERBB2 | |
| SCHEMBL676613 | 0.79 | MAP2K1 (0.78) | EGFRMAP2K1ERBB2RAF1 | |
| SCHEMBL29556194 | 0.79 | MAP2K1 (0.78) | EGFRMAP2K1ERBB2RAF1 | |
| SCHEMBL7018285 | 0.78 | SRC (0.76) | SRC | |
| SCHEMBL28756490 | 0.78 | MAP2K1 (0.95) | SRCEGFRGAKMAP2K1ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020026052-A1 | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-02-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020026052-A1 | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | PKD1, PKD2, CSNK1A1 | SRC 237/4885EGFR 527/4885GAK 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.